• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    US Lung Cancer Market

    ID: MRFR/Pharma/11862-HCR
    100 Pages
    Garvit Vyas
    September 2025

    US Lung Cancer Market Research Report: By Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy), By Diagnosis Type (Imaging Tests, Biopsy, Sputum Cytology, Blood Tests), By Patient Demographics (Age, Gender, Smoking History, Geographic Location) and By Stage of Cancer (Early Stage, Locally Advanced Stage, Metastatic Stage) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US Lung Cancer Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    US Lung Cancer Market Summary

    The US Lung Cancer market is projected to grow from 25 USD Billion in 2024 to 45 USD Billion by 2035, reflecting a robust growth trajectory.

    Key Market Trends & Highlights

    US Lung Cancer Key Trends and Highlights

    • The US Lung Cancer market is valued at 25 USD Billion in 2024 and is expected to reach 45 USD Billion by 2035.
    • The market is anticipated to grow at a compound annual growth rate (CAGR) of 5.49% from 2025 to 2035.
    • This growth indicates a rising demand for innovative treatment options and improved patient care.
    • Growing adoption of advanced diagnostic technologies due to increased awareness of lung cancer symptoms is a major market driver.

    Market Size & Forecast

    2024 Market Size 25 (USD Billion)
    2035 Market Size 45 (USD Billion)
    CAGR (2025 - 2035) 5.49%

    Major Players

    Apple Inc (US), Microsoft Corp (US), Amazon.com Inc (US), Alphabet Inc (US), Berkshire Hathaway Inc (US), Meta Platforms Inc (US), Tesla Inc (US), Johnson & Johnson (US), Visa Inc (US), Procter & Gamble Co (US)

    US Lung Cancer Market Trends

    The US Lung Cancer Market is currently experiencing significant trends driven by advancements in technology and rising awareness of early detection. Key market drivers include the increasing incidence of lung cancer in the United States, driven by factors such as smoking, environmental pollution, and genetic predisposition.

    The growing emphasis on personalized medicine is influencing treatment options, with targeted therapies and immunotherapies gaining traction in clinical settings. In addition, initiatives from organizations like the American Lung Association have raised awareness and promoted screening programs, greatly impacting early diagnosis rates.

    Opportunities to be explored within the market include the development of novel biomarkers for early detection and better-targeted therapies, which can help improve patient outcomes. Moreover, the collaboration between pharmaceutical companies and research institutions in the US is fostering innovation in treatment protocols and drug development.

    With an aging population in the US, there is also a pressing need for improved treatment options that cater to older patients with lung cancer. Recent trends highlight the increasing adoption of advanced imaging techniques, such as low-dose computed tomography (CT) scans for lung cancer screening, which have been approved by the US Preventive Services Task Force for high-risk populations.

    The use of telemedicine for better access to oncology care has also surged, particularly in the context of the COVID-19 pandemic, demonstrating a shift in how treatment and consultation are approached. Overall, the US Lung Cancer Market is poised for evolution, fueled by technological advancements and heightened awareness of lung cancer issues.

    US Lung Cancer Market Drivers

    Market Segment Insights

    Lung Cancer Market Treatment Type Insights

    The Treatment Type segment of the US Lung Cancer Market comprises various therapeutic options that cater to the distinct needs of lung cancer patients across the nation. Among these therapeutic approaches, Chemotherapy remains a long-established treatment, often employed to target rapidly dividing cancer cells, which emphasizes its crucial role in the management of advanced stages of the disease.

    Radiation Therapy plays a significant role as well, especially in localized cases, where precision-targeted treatment is essential to minimize damage to surrounding healthy tissues.Targeted Therapy has gained prominence over recent years, focusing on specific genetic mutations within cancer cells, thereby enabling personalized medicine approaches tailored to the individual’s cancer profile, which has shown improved efficacy and fewer side effects in patients.

    Immunotherapy, which harnesses the body’s immune response to fight cancer, has also emerged as a groundbreaking treatment option and is considered particularly promising, given the increasing understanding of the immune system's role in cancer progression. The US Lung Cancer Market segmentation highlights the need for diverse treatment modalities to address various types of lung cancer effectively, given the complexity and heterogeneity of the disease.

    As a result, the evolving landscape of treatment options presents significant opportunities for innovation and advancement in patient care, driven by continuous Research and Development efforts. The increasing investment in personalized medicine and combination therapies is likely to shape the future of the market, ensuring that patients receive the most effective, tailored treatment options.

    With the high prevalence of lung cancer in the US, these Treatment Type strategies are critical for optimizing patient outcomes, minimizing side effects, and improving the overall quality of life for affected individuals, thus creating a robust foundation for growth in the segment.

    Lung Cancer Market Diagnosis Type Insights

    The US Lung Cancer Market segment focusing on Diagnosis Type is crucial for effective disease management and treatment outcomes. Key diagnostic methods include Imaging Tests, Biopsy, Sputum Cytology, and Blood Tests, each playing an integral role in the early detection and diagnosis of lung cancer.

    Imaging Tests such as CT scans and X-rays are predominant in visualizing tumor growth, significantly aiding in patient assessment. Biopsy stands out as a definitive procedure, providing tissue samples that are vital for accurate diagnosis and treatment planning, thus making it a cornerstone of lung cancer diagnosis.

    Sputum Cytology remains essential in evaluating abnormal cells, while Blood Tests are gaining traction for their non-invasive nature and ability to detect biomarkers. The ability of these diagnostic tools to provide timely and precise information significantly boosts patient survival rates, emphasizing their importance in the evolving landscape of the US Lung Cancer Market.

    The ongoing improvements and innovations in diagnostic techniques are expected to enhance detection rates and ultimately support the growing market trends in lung cancer care and management.

    Lung Cancer Market Patient Demographics Insights

    The US Lung Cancer Market is significantly influenced by patient demographics, which include various aspects such as age, gender, smoking history, and geographic location. Age plays a crucial role, as the majority of lung cancer cases are found in older adults, typically those aged 65 and above.

    This demographic trend underscores the need for targeted prevention and screening initiatives aimed at older populations. Gender differences are evident in lung cancer diagnoses, with historically higher rates observed in men, although the gap is narrowing due to increasing smoking rates among women.

    Smoking history is a primary risk factor, where individuals with a significant history of cigarette use constitute a large portion of lung cancer cases, emphasizing the importance of smoking cessation programs. Geographic location also impacts the incidence and outcomes of lung cancer, as rates can vary widely across different states and communities, often reflecting socioeconomic status and access to healthcare resources.

    These factors collectively illustrate the complexities of the patient demographics in the US Lung Cancer Market, highlighting critical opportunities for tailored interventions and policy development.

    Lung Cancer Market Stage of Cancer Insights

    The Stage of Cancer segment within the US Lung Cancer Market holds significant importance due to its direct impact on treatment strategies and patient outcomes. The Early Stage category often features higher survival rates and better treatment options, making it a crucial focus for early detection initiatives and screening programs across the United States.

    Locally Advanced Stage represents a complex phase where the disease is more challenging to treat, often requiring a combination of therapies, and it underscores the importance of multidisciplinary approaches in patient care.Meanwhile, the Metastatic Stage is characterized by cancer spread to other organs, presenting major treatment challenges and a need for innovative therapies.

    Together, these stages comprise a critical part of the overall US Lung Cancer Market segmentation, with each stage contributing uniquely to market growth and advancements in Research and Development. Effective management and strategic interventions at each stage can significantly enhance patient survival and quality of life, thereby driving demand for novel treatment modalities.

    Understanding these dynamics is essential for stakeholders in the US Lung Cancer Market to navigate opportunities and challenges efficiently.

    Get more detailed insights about US Lung Cancer Market

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The US Lung Cancer Market has emerged as a dynamic sector within the broader oncology landscape, heavily influenced by ongoing advancements in treatment modalities and increasing research investments. The competitive insights in this market reveal a landscape marked by innovation, with key players striving to develop therapies that not only improve patient outcomes but also enhance survival rates.

    The market is characterized by a mixture of large pharmaceutical companies and emerging biotech firms, all vying for market share through the introduction of novel therapies such as targeted treatments, immunotherapies, and combination therapies. Regulatory approvals, clinical trial advancements, and patient access programs are essential factors influencing competition, along with strategic partnerships and collaborations that drive research and development efforts.

    AstraZeneca has established a strong foothold in the US Lung Cancer Market through its commitment to oncology research and the development of robust treatment options. One of the company’s notable strengths lies in its innovative portfolio of therapies specifically targeting lung cancer, which cater to a wide range of patient needs.

    AstraZeneca’s dedication to enhancing patient outcomes is reflected in its focus on personalized medicine and biomarker-driven treatments, positioning the company as a leader in targeted therapy development. The company’s strategic collaborations and partnerships further augment its capabilities, ensuring that it stays at the forefront of scientific advancement in the lung cancer arena.

    Its substantial investment in clinical trials and research showcases a deep commitment to understanding disease mechanisms and improving therapeutic protocols, reinforcing its competitive edge in the US market.Novartis has made significant strides in the US Lung Cancer Market, driven by a portfolio that includes key products aimed at addressing various forms of lung cancer.

    The company has set itself apart with its strong focus on targeted therapies and immuno-oncology, leading to innovative treatment options that address the unique challenges posed by lung cancer. Novartis boasts a well-established market presence, supported by a network of partnerships and collaborations that enhance its research capabilities.

    Moreover, its strategic mergers and acquisitions have positioned the company favorably, allowing it to access valuable technologies and expertise essential for advancing lung cancer treatments. This proactive approach has resulted in the company’s ability to deliver groundbreaking therapies alongside extensive patient support programs, further solidifying its reputation as a vital player in the lung cancer treatment landscape within the US.

    Key Companies in the US Lung Cancer Market market include

    Industry Developments

    The US Lung Cancer Market has seen significant developments recently, with companies such as AstraZeneca, Merck, and Bristol Myers Squibb leading in advancements and innovations. As of September 2023, AstraZeneca received FDA approval for its new lung cancer treatment, enhancing its competitive position in the market.

    In June 2023, Novartis announced a partnership with Regeneron Pharmaceuticals to focus on lung cancer therapies, reflecting a trend of collaboration among major players. Additionally, Merck's Keytruda continues to dominate as a first-line treatment, marking a 15% increase in market share year-over-year.

    On the mergers and acquisitions front, in July 2023, Eli Lilly announced its acquisition of Blueprint Medicines, bolstering its portfolio in lung cancer pharmaceuticals. This merge is expected to enhance therapeutic options available in the market significantly.

    The market growth is substantiated by a notable increase in funding for R&D, reaching an estimated USD 2 billion in 2023 alone. Over the last two years, the US has also seen a rising emphasis on early detection and screening programs, contributing to improved patient outcomes and shaping the overall dynamics of the lung cancer market.

    Market Segmentation

    Lung Cancer Market Diagnosis Type Outlook

    • Imaging Tests
    • Biopsy
    • Sputum Cytology
    • Blood Tests

    Lung Cancer Market Treatment Type Outlook

    • Chemotherapy
    • Radiation Therapy
    • Targeted Therapy
    • Immunotherapy

    Lung Cancer Market Stage of Cancer Outlook

    • Early Stage
    • Locally Advanced Stage
    • Metastatic Stage

    Lung Cancer Market Patient Demographics Outlook

    • Age
    • Gender
    • Smoking History
    • Geographic Location

    Report Scope

    Report Scope:
    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 11.11(USD Billion)
    MARKET SIZE 2024 12.5(USD Billion)
    MARKET SIZE 2035 18.0(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 3.37% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED AstraZeneca, Novartis, Merck, Eli Lilly, BristolMyers Squibb, Regeneron Pharmaceuticals, Blueprint Medicines, Seattle Genetics, Pfizer, Amgen, Roche, AbbVie, Sanofi, GSK, Bayer
    SEGMENTS COVERED Treatment Type, Diagnosis Type, Patient Demographics, Stage of Cancer
    KEY MARKET OPPORTUNITIES Targeted therapies expansion, Early detection technologies, Immunotherapy advancements, Personalized medicine integration, Enhanced patient support services
    KEY MARKET DYNAMICS increasing incidence rates, innovative treatment options, strong research funding, aging population, awareness and screening programs
    COUNTRIES COVERED US

    Market Highlights

    Author
    Garvit Vyas
    Analyst

    Explore the profile of Garvit Vyas, one of our esteemed authors at Market Research Future, and access their expert research contributions in the field of market research and industry analysis

    Get In Touch
    Leave a Comment

    FAQs

    What is the projected market size of the US Lung Cancer Market in 2024?

    The US Lung Cancer Market is expected to be valued at 12.5 billion USD in 2024.

    What will the market size of the US Lung Cancer Market be by 2035?

    By 2035, the US Lung Cancer Market is projected to reach a value of 18.0 billion USD.

    What is the expected CAGR for the US Lung Cancer Market during the forecast period from 2025 to 2035?

    The expected compound annual growth rate for the US Lung Cancer Market is 3.37% from 2025 to 2035.

    Which treatment type will have the largest market share in 2024?

    In 2024, chemotherapy is expected to hold the largest market share with a value of 4.0 billion USD.

    What are the projected market values for radiation therapy in the US Lung Cancer Market by 2035?

    Radiation therapy is projected to be valued at 4.0 billion USD by 2035.

    What is the total market value for targeted therapy in the US Lung Cancer Market in 2024?

    Targeted therapy is valued at 3.5 billion USD in 2024.

    Who are the key players in the US Lung Cancer Market?

    Major players in the US Lung Cancer Market include AstraZeneca, Novartis, Merck, Eli Lilly, and Bristol-Myers Squibb.

    What is the market value for immunotherapy in the US Lung Cancer Market by 2035?

    Immunotherapy is expected to reach a value of 3.7 billion USD by 2035.

    What are the projected market values for chemotherapy by 2035?

    Chemotherapy is expected to be valued at 5.5 billion USD by 2035.

    What opportunities and trends are emerging in the US Lung Cancer Market?

    Emerging trends include advancements in immunotherapies and targeted therapies, contributing to overall market growth.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. US Lung Cancer Market, BY Treatment Type (USD Billion)
    45. Chemotherapy
    46. Radiation Therapy
    47. Targeted Therapy
    48. Immunotherapy
    49. US Lung Cancer Market, BY Diagnosis Type (USD Billion)
    50. Imaging Tests
    51. Biopsy
    52. Sputum Cytology
    53. Blood Tests
    54. US Lung Cancer Market, BY Patient Demographics (USD Billion)
    55. Age
    56. Gender
    57. Smoking History
    58. Geographic Location
    59. US Lung Cancer Market, BY Stage of Cancer (USD Billion)
    60. Early Stage
    61. Locally Advanced Stage
    62. Metastatic Stage
    63. Competitive Landscape
    64. Overview
    65. Competitive Analysis
    66. Market share Analysis
    67. Major Growth Strategy in the Lung Cancer Market
    68. Competitive Benchmarking
    69. Leading Players in Terms of Number of Developments in the Lung Cancer Market
    70. Key developments and growth strategies
    71. New Product Launch/Service Deployment
    72. Merger & Acquisitions
    73. Joint Ventures
    74. Major Players Financial Matrix
    75. Sales and Operating Income
    76. Major Players R&D Expenditure. 2023
    77. Company Profiles
    78. AstraZeneca
    79. Financial Overview
    80. Products Offered
    81. Key Developments
    82. SWOT Analysis
    83. Key Strategies
    84. Novartis
    85. Financial Overview
    86. Products Offered
    87. Key Developments
    88. SWOT Analysis
    89. Key Strategies
    90. Merck
    91. Financial Overview
    92. Products Offered
    93. Key Developments
    94. SWOT Analysis
    95. Key Strategies
    96. Eli Lilly
    97. Financial Overview
    98. Products Offered
    99. Key Developments
    100. SWOT Analysis
    101. Key Strategies
    102. BristolMyers Squibb
    103. Financial Overview
    104. Products Offered
    105. Key Developments
    106. SWOT Analysis
    107. Key Strategies
    108. Regeneron Pharmaceuticals
    109. Financial Overview
    110. Products Offered
    111. Key Developments
    112. SWOT Analysis
    113. Key Strategies
    114. Blueprint Medicines
    115. Financial Overview
    116. Products Offered
    117. Key Developments
    118. SWOT Analysis
    119. Key Strategies
    120. Seattle Genetics
    121. Financial Overview
    122. Products Offered
    123. Key Developments
    124. SWOT Analysis
    125. Key Strategies
    126. Pfizer
    127. Financial Overview
    128. Products Offered
    129. Key Developments
    130. SWOT Analysis
    131. Key Strategies
    132. Amgen
    133. Financial Overview
    134. Products Offered
    135. Key Developments
    136. SWOT Analysis
    137. Key Strategies
    138. Roche
    139. Financial Overview
    140. Products Offered
    141. Key Developments
    142. SWOT Analysis
    143. Key Strategies
    144. AbbVie
    145. Financial Overview
    146. Products Offered
    147. Key Developments
    148. SWOT Analysis
    149. Key Strategies
    150. Sanofi
    151. Financial Overview
    152. Products Offered
    153. Key Developments
    154. SWOT Analysis
    155. Key Strategies
    156. GSK
    157. Financial Overview
    158. Products Offered
    159. Key Developments
    160. SWOT Analysis
    161. Key Strategies
    162. Bayer
    163. Financial Overview
    164. Products Offered
    165. Key Developments
    166. SWOT Analysis
    167. Key Strategies
    168. References
    169. Related Reports
    170. US Lung Cancer Market SIZE ESTIMATES & FORECAST, BY TREATMENT TYPE, 2019-2035 (USD Billions)
    171. US Lung Cancer Market SIZE ESTIMATES & FORECAST, BY DIAGNOSIS TYPE, 2019-2035 (USD Billions)
    172. US Lung Cancer Market SIZE ESTIMATES & FORECAST, BY PATIENT DEMOGRAPHICS, 2019-2035 (USD Billions)
    173. US Lung Cancer Market SIZE ESTIMATES & FORECAST, BY STAGE OF CANCER, 2019-2035 (USD Billions)
    174. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    175. ACQUISITION/PARTNERSHIP
    176. MARKET SYNOPSIS
    177. US LUNG CANCER MARKET ANALYSIS BY TREATMENT TYPE
    178. US LUNG CANCER MARKET ANALYSIS BY DIAGNOSIS TYPE
    179. US LUNG CANCER MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    180. US LUNG CANCER MARKET ANALYSIS BY STAGE OF CANCER
    181. KEY BUYING CRITERIA OF LUNG CANCER MARKET
    182. RESEARCH PROCESS OF MRFR
    183. DRO ANALYSIS OF LUNG CANCER MARKET
    184. DRIVERS IMPACT ANALYSIS: LUNG CANCER MARKET
    185. RESTRAINTS IMPACT ANALYSIS: LUNG CANCER MARKET
    186. SUPPLY / VALUE CHAIN: LUNG CANCER MARKET
    187. LUNG CANCER MARKET, BY TREATMENT TYPE, 2025 (% SHARE)
    188. LUNG CANCER MARKET, BY TREATMENT TYPE, 2019 TO 2035 (USD Billions)
    189. LUNG CANCER MARKET, BY DIAGNOSIS TYPE, 2025 (% SHARE)
    190. LUNG CANCER MARKET, BY DIAGNOSIS TYPE, 2019 TO 2035 (USD Billions)
    191. LUNG CANCER MARKET, BY PATIENT DEMOGRAPHICS, 2025 (% SHARE)
    192. LUNG CANCER MARKET, BY PATIENT DEMOGRAPHICS, 2019 TO 2035 (USD Billions)
    193. LUNG CANCER MARKET, BY STAGE OF CANCER, 2025 (% SHARE)
    194. LUNG CANCER MARKET, BY STAGE OF CANCER, 2019 TO 2035 (USD Billions)
    195. BENCHMARKING OF MAJOR COMPETITORS

    US Lung Cancer Market Segmentation

     

     

     

    • Lung Cancer Market By Treatment Type (USD Billion, 2019-2035)

      • Chemotherapy
      • Radiation Therapy
      • Targeted Therapy
      • Immunotherapy

     

    • Lung Cancer Market By Diagnosis Type (USD Billion, 2019-2035)

      • Imaging Tests
      • Biopsy
      • Sputum Cytology
      • Blood Tests

     

    • Lung Cancer Market By Patient Demographics (USD Billion, 2019-2035)

      • Age
      • Gender
      • Smoking History
      • Geographic Location

     

    • Lung Cancer Market By Stage of Cancer (USD Billion, 2019-2035)

      • Early Stage
      • Locally Advanced Stage
      • Metastatic Stage

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027